Biotechnology updates: EVOFEM

EVOFEM

Evofem is the provider of Phexxi, the first and only FDA- approved hormone-free, woman- controlled contraceptive gel that women use on demand. Because Phexxi is anon-hormonal birth control system, it isn't associated with common side goods like depression, weight gain, headaches, mood swings, perversity, and reduced libido. Taking hormones may not be right for some women, especially those with certain medical conditions including clotting diseases, cancer, a BMI over 30, and diabetes; women who are bone feeding; and women who bomb. further than 23 million women in theU.S. don't want to get pregnant and won't use hormonal contraception, so the unmet need for an invention like Phexxi is significant. Implicit strategic druthers
to be explored or estimated as part of this process may include, but aren't limited to, a junction, rear junction, other business combination, deals of means, licensing or other strategic deals involving the Company. Evofem doesn't anticipate to expose developments with respect to this process unless until the evaluation of strategic druthers
has been completed or the Board of Directors has concluded exposure is applicable or fairly needed. Joseph Gunnar &Co., LLC has been retained as the Company's exclusive fiscal counsel to help in this review process

About Evofem

Evofem Biosciences,Inc., is developing and commercializing innovative products to address unmet requirements in women's sexual and reproductive health. The Company's first FDA- approved product, Phexxi ®( lactic acid, citric acid and potassium bitartrate), is a hormone-free, on- demand tradition contraceptive vaginal gel. It comes in a box of 12pre-filled applicators and is applied 0- 60 twinkles before each act of coitus Forward- Looking Statements This press release includes" forward- looking statements," within the meaning of the safe harbor for forward- looking statements handed by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the process to explore and estimate strategic druthers
and implicit issues thereof. There can be no assurance of a successful outgrowth from these sweats, or of the form or timing of any similar outgrowth. You're advised not to place overdue reliance on these forward- looking statements, which are current only as of the date of this press release. Each of these forward- looking statements involves pitfalls and misgivings. Important factors that could beget factual results to differ materially from those bandied or inferred in the forward- looking statements are bared in the Company's SEC forms, including its Annual Report on Form 10- K for the time ended December 31, 2021, filed with the SEC on March 10, 2022, its Daily Report on Form 10- Q for the quarter ended September 30, 2022 filed with the SEC on January 6, 2023 and any posterior forms. All forward- looking statements are expressly good in their wholeness by similar factors. The Company doesn't take over any duty to modernize any forward- looking statement except as needed by law.